Circulated Activated Platelets and Increased Platelet Reactivity in Patients With Behçet’s Disease

Abstract

Behçet’s disease (BD) is a multisystem disorder. Venous as well as arterial thrombosis is a common complication of BD but exact pathogenetic mechanism of the thrombotic tendency is not well known. This study aimed to evaluate circulating activated platelets and platelet reactivity in Behçet’s patients. Twenty-two Behçet’s patients (4 female, 18 male; mean age 38.6 ± 10.9 years) and 20 control subjects (8 female, 12 male; mean age 38.8 ± 9.4 years) were included. Those patients who had hypertension, hyperlipidemia, peripheral or coronary artery disease, hepatic or renal function abnormality, and who were using aspirin and other platelet-active drugs were excluded. Platelet activity and reactivity to adenosine diphosphate (ADP) were measured by whole blood flow cytometry. We assessed markers of platelet degranulation (P-selectin; CD62P) and the activated glycoprotein IIb/IIIa receptor (PAC1 binding to fibrinogen binding site) before and after stimulation with ADP. Platelet P-selectin expression was not significantly different between patients and control subjects both at baseline (p=0.420) and after stimulation (p=0.56). Baseline (p=0.001) and ADP-stimulated (p=0.003) PAC1 binding was significantly higher in Behçet’s patients than in the control group. Clinical activity has no effect on P-selectin expression and PAC1 binding. There is evidence of platelet activity and hyperreactivity in patients with BD and this may contribute to a prothrombotic state. In addition to aspirin, other antiplatelet drugs may be useful in the prevention and treatment of thrombosis in Behçet’s patients.

Keywords

Behçet’s disease Platelet activity Platelet reactivity Platelet degranulation Glycoprotein IIb/IIIa receptor

References

Yurdakul S , Hanmuryudan V , Yazici H. Behçet's syndrome. Curr Opin Rheumatol 2004; 16: 38-38.

Sakane T , Takeno M , Suzuki N , Inaba G. Behçet's disease. N Engl J Med 1999; 341(17): 1284-1284.

Koc Y , Gullu I , Akpek G , et al. Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-402.

Kiraz S , Ertenli I , Ozturk MA , et al. Pathological haemostasis and “prothrombotic state” in Behçet's disease. Thromb Res 2002; 105(2): 125-125.

Gul A. Behçet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001; 19(Suppl 24): S6-S6.

Kosar A , Mustafa O , Haznedaroglu IC , Karaaslan Y. Hemostatic parameters in Behçet's disease: A reappraisal. Rheumatol Int 2002; 22: 9-9.

Espinosa G , Font J , Tassies D , et al. Vascular involvement in Behçet's disease: Relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-37.

Akarsu M , Demirkan F , Özsan GH , et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am J Hematol 2001; 68: 225-225.

Sengul N , Demirer S , Yerdel MA , et al. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. World J Surg 2000; 24: 1584-1584.

10.

Haim S , Brook JG , Gilhar A , et al. Platelet function in Behçet's disease. J Dermatol 1984; 11(2): 117-117.

11.

Wilson AP , Efthimiou J , Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest 1988; 18(4): 410-410.

12.

Nakano H , Oka H , Matsuda T , et al. Spontaneous platelet aggregation in patients with Behçet's disease by using laser-light scattering aggregometer. Adv Exp Med Biol 2003; 528: 437-437.

13.

Tunc SE , Aksu K , Keser G , et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet's patients. Rheumatol Int 2005; 25: 326-326.

14.

Schmitz G , Rothe G , Ruf A , et al. European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-885.

15.

Michelson AD , Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6(5): 342-342.

16.

Michelson AD , Barnard MR , Krueger LA , et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21(3): 259-259.

17.

Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-298.

18.

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335 (8697): 1078-1078.

19.

Shattil SJ , Cunningham M , Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70(1): 307-307.

20.

Payrastre B , Missy K , Trumel C , et al. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 2000; 60(8): 1069-1069.

21.

Shattil SJ , Kashiwagi H , Pampori N. Integrin signaling: The platelet paradigm. Blood 1998; 91(8): 2645-2645.

22.

Peerschke EI. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost 1995; 73 (5): 862-862.

23.

Stathakis NE , Economopoulos TC , Papayannis AG , Thomopoulos D. Platelet function, blood coagulation and fibrinolysis in Behçet's syndrome. Blut 1977; 34(3): 215-215.

24.

Thompson NT , Scrutton MC , Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: Dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986; 41(5): 615-615.

25.

Plow EF , Pierschbacher MD , Ruoslahti E , et al. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985; 82(23): 8057-8057.

26.

Michelson AD , Barnard MR , Hechtman HB , et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-11877.

27.

Michelson AD , Benoit SE , Kroll MH , et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994; 83 (12): 3562-3562.

28.

Haznedaroglu E , Karaaslan Y , Buyukasik Y , et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis 2000; 59(1): 61-61.

29.

Hizli N , Sahin G , Sahin F , et al. Plasma prostacyclin levels in Behçet's disease. Lancet 1985; 1(8443): 1454-1454.

30.

Haznedaroglu IC , Dundar S , Kiraz S. Eicosanoids in the prethrombotic state of Behçet's disease. Thromb Res 1995; 80(5): 445-445.

31.

Kleiman NS , Raizner AE , Jordan R , et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26(7): 1665-1665.